TORONTO--(BUSINESS WIRE)-- Cybin Inc. (CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative ...

Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and ...

SAB Biotherapeutics ( (SABS)) has provided an update. On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with UBS Securities LLC to establish an at-the-market equity ...

TORONTO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Brookfield Global Infrastructure Securities Income Fund (the “Fund”) (TSX: BGI.UN) is pleased to announce that it is renewing its at-the-market equity ...

Beyond Meat (BYND) gets a Sell rating as revenues slide, losses persist, and dilution hurts value despite debt cuts. Read ...

Quantum Biopharma ( (TSE:QNTM)) has issued an update. On December 22, 2025, Quantum BioPharma Ltd. announced that it had entered into an at-the-market offering agreement with Rodman & Renshaw LLC, ...

Strategy keeps buying Bitcoin during downturns by tapping equity markets and reserves, turning dilution and financing costs into a repeatable Bitcoin accumulation strategy. Strategy funds its dip ...

ATLANTA--(BUSINESS WIRE)--Volato Group, Inc. (the “Company” or “Volato”) (NYSE American: SOAR), today announced that it has elected to pause its at-the-market equity offering program (“ATM”) through ...

Strategy Inc. (NASDAQ: MSTR) bought 1,287 Bitcoin (CRYPTO: BTC) between Dec. 29 and Jan. 4, pushing total holdings to 673,783 BTC. Strategy sold just under 2 million shares of common stock through its ...

Michael Saylor’s Strategy bought 1,286 BTC for $116 million, raising its Bitcoin holdings to 673,783 BTC and U.S. dollar reserves to $2.25 billion. Michael Saylor’s Strategy, the Tysons Corner, ...

After market close on Tuesday, FuelCell said in a filing it entered into an amended sales agreement to increase the amount of shares that may be sold under its sales agreement to $200 million.

Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel ...